UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions.
Expert Rev Clin Pharmacol
; 15(4): 473-485, 2022 Apr.
Article
en En
| MEDLINE
| ID: mdl-34937477
ABSTRACT
OBJECTIVES:
To explore pain-specific, general health-related quality of life (HRQoL), and safety outcomes of chronic pain patients prescribed cannabis-based medicinal products (CBMPs).METHODS:
A case series was performed using patients with chronic pain from the UK Medical Cannabis Registry. Primary outcomes were changes in Brief Pain Inventory short-form (BPI), Short-form McGill Pain Questionnaire-2 (SF-MPQ-2), Visual Analogue Scale-Pain (VAS), General Anxiety Disorder-7 (GAD-7), Sleep Quality Scale (SQS), and EQ-5D-5L, at 1, 3, and 6 months from baseline. Statistical significance was defined at p-value<0.050.RESULTS:
190 patients were included. Median initial Δ9-tetrahydrocannabinol and cannabidiol daily doses were 2.0mg (range0.0-442.0mg) and 20.0mg (range0.0-188.0mg) respectively. Significant improvements were observed within BPI, SF-MPQ-2, GAD-7, SQS, EQ-5D-5 L index, and VAS measures at all timepoints (p<0.050). Seventy-five adverse events (39.47%) were reported, of which 37 (19.47%) were rated as mild, 23 (12.11%) as moderate, and 14 (7.37%) as severe. Nausea (n=11; 5.8%) was the most frequent adverse event.CONCLUSION:
An association was identified between patients with chronic pain prescribed CBMPs and improvements in pain-specific and general HRQoL outcomes. Most adverse events were mild to moderate in severity, indicating CBMPs were well tolerated. Inherent limitations of study design limit its overall applicability.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Dolor Crónico
/
Marihuana Medicinal
Límite:
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
Expert Rev Clin Pharmacol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Reino Unido